Andere talen Gossamer Bio, Inc.

Aandelen

GOSS

US38341P1021

Geschatte realtime Cboe BZX Andere beurzen 21:03:28 26-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,914 ^USD	-9,50%		+58,75%	-1,10%

12/06	Transcript : Gossamer Bio, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 01:20 PM
07/05	Gossamer Bio, Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	07/06
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference	14/05
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	10/05
Gossamer Bio: Q1 Earnings Snapshot	07/05
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update	07/05
Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Gossamer bio announces publication of torrey phase 2 results in the lancet respiratory medicine	06/05
Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications	06/05
Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment	06/05
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications	06/05
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine	03/05
Gossamer Bio Announces Publication of Torrey Phase 2 Results in the Lancet Respiratory Medicine	03/05
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors	12/03
Gossamer Bio Announces Board of Directors Appointments	12/03
Gossamer Bio: Q4 Earnings Snapshot	05/03
Gossamer Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update	05/03
Gossamer Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	05/03
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	08/01
Gossamer Bio, Inc.(NasdaqGS:GOSS) dropped from NASDAQ Biotechnology Index	15/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Gossamer Bio, Inc.

Aandelen

GOSS

US38341P1021

Andere talen

Filters